You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

463 Results
Drug
Other Name(s): Busulfex® , Myleran®
Jun 2019
Drug
Other Name(s): Sprycel®
Feb 2025
Drug
Other Name(s): Firmagon®
Feb 2025
Drug
Jun 2025
Drug
Other Name(s): Casodex® (multiple brands available)
Apr 2024
Drug
Nov 2024
Drug
Other Name(s): Treanda®
Nov 2024
Drug
Other Name(s): Adcetris®
Jun 2025
Drug
Other Name(s): Tafinlar®
Jun 2025
Drug
Other Name(s): Bosulif®
Nov 2024
Drug
Other Name(s): Blincyto®
Nov 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
Feb 2025

Pages